Patents by Inventor Matthew G. Laporte

Matthew G. Laporte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMAC mimetic
    Patent number: 11951147
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 9, 2024
    Assignee: MEDIVIR AB
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • HDAC INHIBITORS
    Publication number: 20240051931
    Abstract: The present disclosure is directed to chromane compounds, chromane compounds demonstrating HDAC inhibition, and pharmaceutical compositions thereof. Additional embodiments include methods of using the chromane compounds. For example, the disclosure includes methods of inhibiting histone acetylation in a cell, comprising contacting the cell with a chromane compound of the disclosure. Additional embodiments include methods of treating a disease capable of treatment by inhibition of histone acetylation in a patient in need thereof, comprising administering a chromane compound of the disclosure.
    Type: Application
    Filed: December 2, 2021
    Publication date: February 15, 2024
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Donna M. Huryn, Matthew G. LaPorte, Leila Terrab, Michael James Houghton, Andrea Topacio, Taber Sarah Maskrey, Tyler Kristufek, Uygar Sozer, Desirae Lynn Crocker, Sipak Joyasawal, Alyssa Thornton, Shikha Singh Chauhan, Mary Liang, Prema Iyer, Jagannath Panda
  • Modulators of p97 AAA ATPase activity
    Patent number: 11773075
    Abstract: The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: October 3, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte
  • SMAC MIMETIC
    Publication number: 20230149500
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Application
    Filed: May 3, 2022
    Publication date: May 18, 2023
    Inventors: Stephen M. CONDON, Yijun DENG, Matthew G. LAPORTE, Susan R. RIPPIN
  • Targeted Nitroxide Compounds and Their Use in Treating Ferroptosis-Related Diseases
    Publication number: 20220259149
    Abstract: Provided herein are compounds useful in the prevention or treatment of ferroptosis in a patient, and methods of preventing or treating ferroptosis, or a treating a condition or disease associated with ferroptosis, such as a patient having a neurodegenerative disease, traumatic brain injury, acute kidney disease, liver injury, ischemia/reperfusion injury, ischemic stroke, intracerebral hemorrhage, liver fibrosis, diabetes, acute myeloid leukemia, age-related macular degeneration, psoriasis, a hemolytic disorder, or an inflammatory disease.
    Type: Application
    Filed: July 27, 2020
    Publication date: August 18, 2022
    Inventors: Peter Wipf, Taber Sarah Maskrey, Matthew G. LaPorte, Manwika Charaschanya
  • SMAC mimetic
    Patent number: 11351221
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: June 7, 2022
    Assignee: MEDIVIR AB
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • METHODS OF TREATMENT USING PHENYL INDOLE ALLOSTERIC INHIBITORS OF P97 ATPASE
    Publication number: 20220112179
    Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 14, 2022
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the United States Department of Health and Human Servi, The Regents of the University of California
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
  • MODULATORS OF P97 AAA ATPASE ACTIVITY
    Publication number: 20220089565
    Abstract: The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte
  • Phenyl indole allosteric inhibitors of P97 ATPase
    Patent number: 11247985
    Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: February 15, 2022
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the U.S. Department of Hearth and Human Services, The Regents of the University of California
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
  • Modulators of P97 AAA ATPase activity
    Patent number: 11214560
    Abstract: The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: January 4, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte
  • 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
    Patent number: 11111253
    Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: September 7, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Jennifer Rubin Grandis, Matthew G. LaPorte, Paul A. Johnston, Mark E. Schurdak, Raffaele Colombo
  • MODULATORS OF P97 AAA ATPASE ACTIVITY
    Publication number: 20210070732
    Abstract: The present invention is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by modulation or inhibition of p97.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 11, 2021
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Donna M. HURYN, Peter Wipf, Matthew G. LaPorte
  • Modulators of P97 AAA ATPase activity
    Patent number: 10894782
    Abstract: The present invention is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by modulation or inhibition of p97.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: January 19, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte
  • 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as Inhibitors of the STAT3 Pathway with Anti-Proliferative Activity
    Publication number: 20200339602
    Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 29, 2020
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Jennifer Rubin Grandis, Matthew G. LaPorte, Paul A. Johnston, Mark E. Schurdak, Raffaele Colombo
  • SMAC Mimetic
    Publication number: 20200282002
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Application
    Filed: February 6, 2020
    Publication date: September 10, 2020
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • MODULATORS OF P97 AAA ATPASE ACTIVITY
    Publication number: 20200216410
    Abstract: The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.
    Type: Application
    Filed: May 10, 2018
    Publication date: July 9, 2020
    Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte
  • PHENYL INDOLE ALLOSTERIC INHIBITORS OF P97 ATPASE
    Publication number: 20200157082
    Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.
    Type: Application
    Filed: January 21, 2020
    Publication date: May 21, 2020
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the United States Department of Health and Human, The Regents of the University of California
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
  • Phenyl indole allosteric inhibitors of p97 ATPase
    Patent number: 10633370
    Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 28, 2020
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the U.S. Department of Health and Human Services, The Regents of the University of California
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
  • 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
    Patent number: 10618914
    Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 14, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Jennifer Rubin Grandis, Matthew G. LaPorte, Paul A. Johnston, Mark E. Schurdak, Raffaele Colombo
  • SMAC mimetic
    Patent number: 10596220
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: March 24, 2020
    Assignee: Medivir AB
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin